Alaxia at North American Cystic Fibrosis Conference

Alaxia at North American Cystic Fibrosis Conference

Alaxia moves forward its promising CF antimicrobial drug candidate at the North American Cystic Fibrosis Conference from October 18th-20th in Denver.

On this occasion, Alaxia will present results on the “Post-antibiotic effect of OSCN-, lactoferrin and ALX-009 on clinical strains isolated from cystic fibrosis patients”. These exciting results confirm the interest of the ALX-009 combination to fight bacterial infections in CF patients.

To get more about Alaxia activities and its innovative First-in-Class orphan drug combination, ALX-009, you can visit the following website :
http://www.alaxia-pharma.eu/